Growing expansion in India
Established in 1999 in Mumbai, Aptar Pharma is the market leader in India. Aptar Pharma provides innovative and proven aerosol, spray and dispensing systems to biotechnology, healthcare and pharmaceutical companies in India.
Located at Rabale, Navi Mumbai, this new facility is the first of its kind. It will be key to furthering Aptar Pharma's commitment to provide world class quality products coupled with the outstanding responsiveness requested by our Indian customers. The facility will fully support our customers' growth in the pharma market.
This new state-of-the-art manufacturing site was officially inaugurated on January 21st, 2012 in the presence of:
• The ACG Worldwide Chairman, Mr. Ajit Singh
• The President of the Indian Pharmaceutical Association (IPA), Dr C. Gopalakrishna Murty
• Business partners and suppliers as well as AptarGroup senior management representatives including our CEO Mr. Stephen J. Hagge and AptarGroup board member Mr. P. Pfeiffer.
This site includes an ISO 7 cleanroom where main production will focus on the DF30 metering valve platform for pMDIs and on spray pump assembly .
Leveraging local employment opportunities
Currently Aptar Pharma India has some 30 employees. With the opening of the new Mumbai manufacturing site, this team will be reinforced with a number of different employment profiles.
Recognized as the market leader in Asia, including India, Aptar Pharma will become a key local employer and will continue to expand its activity, leveraging an in-depth network of local partners to forge strong links with a wide range of local players, including those in research, industry, academia and regulatory bodies.
“With the launch of the second Aptar Pharma manufacturing site in Asia, after Suzhou in China, we are on track to meet our main objective of better serving Indian customers by providing locally manufactured devices”, said Marc Prieur, President Aptar Pharma Asia. “This state-of-the-art manufacturing site, along with a highly skilled local team, shows Aptar Pharma's strong commitment to the Indian Pharmaceutical industry”.
Companies in this article
![“Another key [UDI] benefit, because we're calling that product by the same name across the healthcare supply chain… rich and robust data that we can access around supply consumption and utilization rates. One of the buzz terms we've heard during the COVID-19 crisis was what's my burn rate? How fast am I going through gowns, masks, gloves?” – Mike Schiller, Senior Director at AHRMM](https://img.healthcarepackaging.com/files/base/pmmi/all/image/2020/08/UDI.5f4d326e41d53.png?auto=format&fit=crop&h=146&w=340)
